findmyKOL
Clinical trialNCT04784247Active, not recruitingPhase 2Interventional

Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

SponsorMemorial Sloan Kettering Cancer CenterEnrollment52Advanced Sarcoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out whether combining the study drugs, lenvatinib and pembrolizumab, is a safe and effective treatment for metastatic soft tissue sarcomas that cannot be removed with surgery.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering Basking Ridge (limited Protocol Activities)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth (limited Protocol Activities)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (limited Protocol Activities)

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Cancer Commack (limited Protocol Activities)

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester (limited Protocol Activities)

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Memorial Sloan Kettering Nassau (limited Protocol Activities)

    Uniondale, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lenvatinib →Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Mar 2021
Primary completion
31 Mar 2027
Completion
31 Mar 2027
Last update posted
21 Apr 2026
Registered enrollment
52
Registry id
NCT04784247
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.